RDY vs. ARGX, ONC, BNTX, TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, and ASND
Should you be buying Dr. Reddy's Laboratories stock or one of its competitors? The main competitors of Dr. Reddy's Laboratories include argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), and Ascendis Pharma A/S (ASND). These companies are all part of the "pharmaceutical products" industry.
Dr. Reddy's Laboratories vs.
Dr. Reddy's Laboratories (NYSE:RDY) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment.
3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 60.3% of argenx shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Comparatively, 2.4% of argenx shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
In the previous week, argenx had 11 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 24 mentions for argenx and 13 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.25 beat argenx's score of 1.04 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media.
Dr. Reddy's Laboratories has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.59, indicating that its stock price is 41% less volatile than the S&P 500.
Dr. Reddy's Laboratories has a net margin of 17.25% compared to argenx's net margin of -2.11%. Dr. Reddy's Laboratories' return on equity of 17.87% beat argenx's return on equity.
argenx received 333 more outperform votes than Dr. Reddy's Laboratories when rated by MarketBeat users. Likewise, 67.28% of users gave argenx an outperform vote while only 59.33% of users gave Dr. Reddy's Laboratories an outperform vote.
Dr. Reddy's Laboratories presently has a consensus price target of $17.00, suggesting a potential upside of 27.10%. argenx has a consensus price target of $687.00, suggesting a potential upside of 12.90%. Given Dr. Reddy's Laboratories' higher probable upside, equities analysts plainly believe Dr. Reddy's Laboratories is more favorable than argenx.
Dr. Reddy's Laboratories has higher revenue and earnings than argenx. Dr. Reddy's Laboratories is trading at a lower price-to-earnings ratio than argenx, indicating that it is currently the more affordable of the two stocks.
Summary
argenx beats Dr. Reddy's Laboratories on 11 of the 19 factors compared between the two stocks.
Get Dr. Reddy's Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for RDY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dr. Reddy's Laboratories Competitors List
Related Companies and Tools
This page (NYSE:RDY) was last updated on 3/25/2025 by MarketBeat.com Staff
Buy RDY Stock Free RDY Stock Alerts